期刊文献+

免疫学标记在弥漫大B细胞淋巴瘤中的预后意义 被引量:2

Prognostic significance of immunological markers in diffuse large B cell lymphoma
下载PDF
导出
摘要 目的探讨弥漫大B细胞淋巴瘤中各免疫学标记的临床预后意义。方法回顾性分析有完整随访资料的新诊断DLBCL病理组织标本78例,进行国际预后指数(IPI)评分,并用免疫组化法分为GCB亚型和non-GCB亚型。分析免疫学亚型和免疫学标记的预后意义。结果 78例DLBCL患者中GCB亚型组33例,non-GCB亚型组45例;生存分析显示GCB亚型组3年总生存期(OS)、无进展生存期(PFS)均明显优于non-GCB亚型组。Cox多因素回归模型分析显示BCL2表达、IPI评分是OS、PFS的独立预后因素(P<0.05)。生存分析表明,non-GCB亚型中BCL2阳性组3年OS、PFS明显低于BCL2阴性组,差异有统计学意义(P<0.05),而GCB亚型中BCL2阳性组与阴性组3年OS、PFS差异无统计学意义。结论免疫学标记可以初步判断DLBCL患者的预后,免疫学亚型结合BCL2表达对预后具有一定的指导意义。 Objective To investigate the clinical prognostic significance of immunological markers in diffuse large B cell lymphoma. Methods The cases of 72 DLBCL pathological tissue samples with complete follow-up data newly were retrospectively analyzed by the immunohistochemical and the IPI was staining, and analyzed. The patients were divided into GCB and non-GCB subtypes prognostic significance of immunophenotypic subtypes and immuno-logical markers was analyzed. Results The GCB subtype group was 33 cases, and non-GCB subtype group was 45 cases in 78 patients with DLBCL;survival analysis showed that the 3-year overall survival(OS) and the progression- free survival(PFS) were significantly better in GCB subtype group than that in non-GCB subtype group. Multivariate analysis showed that BCL2 expression and international prognostic index were independent prognostic factors for OS and PFS. Survival analysis showed that the 3-year of OS and PFS were significantly lower in BCL2 positive group than that in negative group for non-GCB subtype, the difference was statistieally significant(P 〈 0.05 ). Then the 3- year of OS and PFS had no significant difference between BCL2 positive group and negative group for GCB subtype. Conclusion The immunological markers can preliminaryly judge the prognosis of patients with DLBCL, and the combination of immunophenotypic subtype and BCL2 has a certain guiding significance on prognosis.
作者 张克娟 杨明珍 Zhang Kejuan Yang Mingzhen(Dept of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei 23002)
出处 《安徽医科大学学报》 CAS 北大核心 2016年第10期1495-1499,共5页 Acta Universitatis Medicinalis Anhui
基金 安徽高校省级自然科学研究项目(编号:KJ2011A164)
关键词 BCL2 弥漫大B细胞淋巴瘤 预后 BCL2 diffuse large B cell lymphoma prognosis
  • 相关文献

参考文献14

  • 1Martelli M, Fen'eri A J, Agostinelli C, et al. Diffuse large B-cell lymphoma [ J ]. Crit Rev Oncol Hematol,2013 , 87 ( 2 ) : 146 - 71. 被引量:1
  • 2Maeshima A M, Taniguchi H, Fukuhara S,et al. Bcl-2, Bcl-6, and the International Prognostic Index are prognostic indicators in patients with diffuse large B-cell lymphoma treated with rituximab- containing chemotherapy[ J ]. Cancer Sei, 2012 , 103 (10) : 1898 - 904. 被引量:1
  • 3Hans C P,Weisenburger D D, Greiner T C, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by im- munohistochemistry using a tissue microarray [ J ]. Blood, 2004, 103(1) : 275 -82. 被引量:1
  • 4Jaffe E S. The 2008 WHO classification of lymphomas: implica- tions for clinical practice and translational research[ J]. Hematolo-gy Am Soc Hematol Educ Program, 2009:523 -31. 被引量:1
  • 5Fu K, Weisenburger D D, Choi W W,et al. Addition of rituximab to standard chemotherapy improves the survival of both the germi- nal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma [ J]. J Clin Oncol, 2008, 26 (28) : 4587 -94. 被引量:1
  • 6Li J M, Hou J, Li L,et al. hnmunohistochemical subtypes of dif- fuse large B-cell lyrnphoma in the head and neck region [ J 1. Genet Mol Res, 2015,14 (2) : 3889 -96. 被引量:1
  • 7Salles G, de Jong D, Xie W, et al. Prognostic significance of im- munohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium [ J ]. Blood, 2011, 117(26) :7070 -8. 被引量:1
  • 8Lu T X, Miao Y, Wu J Z,et al. The distinct clinical features and prognosis of the CD10 MUM1 and CD10- Bcl6- MUM1 - dif- fuse large B-cell lymphoma[ J]. Sci Rep, 2016, 6:20465. 被引量:1
  • 9Jovanovie M P, Mihaljevie B, Jakovic L,et al. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non gexaninal center Bcelllikesubtypes[J]. JBUON, 2015,20(3) :820-8. 被引量:1
  • 10De Mello C A, De Andrade V P, De Lima V C, et al. Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma [ J ]. Leuk Lymphoma, 2011, 52(8) :1495 -503. 被引量:1

同被引文献21

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部